aTyr Pharma, Inc. (LIFE): Price and Financial Metrics
GET POWR RATINGS... FREE!
LIFE Stock Price Chart Interactive Chart >
LIFE Price/Volume Stats
| Current price | $2.30 | 52-week high | $6.62 |
| Prev. close | $2.25 | 52-week low | $2.00 |
| Day low | $2.26 | Volume | 110,602 |
| Day high | $2.33 | Avg. volume | 139,285 |
| 50-day MA | $2.23 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 65.84M |
aTyr Pharma, Inc. (LIFE) Company Bio
aTyr Pharma, Inc. is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. aTyr research and development focuses on the extracellular functionality and signaling pathways of tRNA synthetases. Over the last ten years, the company has developed an international portfolio of intellectual property, including 20 human tRNA synthetases and over 300 protein compositions patented. Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. aTyr’s headquarters is located in San Diego, California and the company employs 42 people.
Latest LIFE News From Around the Web
Below are the latest news stories about ATYR PHARMA INC that investors may wish to consider to help them evaluate LIFE as an investment opportunity.
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or FibrosisPatent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care.SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice of Allowance for a patent covering methods for the use of histidyl-tRNA synthetase (HARS) Fc fusion pr |
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of SarcoidosisGlobal pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in EuropeSAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of sarcoidosis based on the opinion of |
aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call TranscriptaTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript November 10, 2022 aTyr Pharma, Inc. reports earnings inline with expectations. Reported EPS is $-0.46 EPS, expectations were $-0.46. Operator: Good afternoon, ladies and gentlemen and welcome to aTyr Pharma’s Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. Later, […] |
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase FragmentLTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform. The target for a naturally occurring fragment of Aspartyl-t |
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 13,200 shares of its common stock, each with an exercise price of $2.38 per share, which is equal to the closing price o |
LIFE Price Returns
| 1-mo | 5.02% |
| 3-mo | -5.35% |
| 6-mo | -38.17% |
| 1-year | -59.58% |
| 3-year | -54.64% |
| 5-year | -95.10% |
| YTD | 5.02% |
| 2022 | -70.68% |
| 2021 | 92.53% |
| 2020 | -6.95% |
| 2019 | -39.95% |
| 2018 | -85.83% |
Continue Researching LIFE
Want to see what other sources are saying about aTYR PHARMA INC's financials and stock price? Try the links below:aTYR PHARMA INC (LIFE) Stock Price | Nasdaq
aTYR PHARMA INC (LIFE) Stock Quote, History and News - Yahoo Finance
aTYR PHARMA INC (LIFE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...